Boston Sci/Nitromed NO more
This article was originally published in The Gray Sheet
Executive Summary
Five-year R&D pact between device powerhouse and Lexington, Mass.-based pharmaceutical company expires without renewal Dec. 31. Boston Scientific and Nitromed were investigating the latter's nitric oxide (NO) technology as a potential complement to paclitaxel in Taxus stents (1"The Gray Sheet" Feb. 9, 2004, p. 20). A Nitromed rep described the exploratory project as "fruitful" but did not cite any resulting product development. The company is seeking other alliances in the device industry for development of its NO technology, which the firm believes could enhance current treatments for cardiovascular disease, pain and asthma...